1.25 / AMA PRA Category 1 CreditTM 0.10 / CEU for Nurses
Provided by the Academy for Continued Healthcare Learning
This activity is supported by an educational grant from Pfizer.
Psoriatic arthritis (PsA) is a chronic, systemic, inflammatory disease with co-occurrence of skin lesions and nail dystrophy, as well as arthritis, spondylitis, enthesitis, and dactylitis. Patients are often undiagnosed or misdiagnosed; yet, untreated persistent inflammation may result in progressive joint damage, severe physical disability, and reduced quality of life. Collaboration between dermatologists and rheumatologists is needed to ensure optimal control of dermal and joint symptoms, and improve long-term outcomes. Novel targets have shown encouraging clinical results in the treatment of psoriasis and/or PsA. Therefore, clinicians need to possess an in-depth knowledge of existing treatment options as well as emerging therapies.
This educational activity is designed for US-based rheumatologists, dermatologists, nurses, and other clinicians on the patient care team who care for patients with psoriatic arthritis.
Upon completion of this activity, participants will be able to:
Discuss the heterogeneous clinical presentation of PsA and collaborative strategies to ensure a prompt, accurate diagnosis
Critically assess the mechanisms of action and efficacy and safety of therapies for PsA
Evaluate the role of new and emerging therapies in current treatment paradigms for newly diagnosed and treatment-experienced PsA patients
Conflict Of Interest Disclosure Policy
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
Jerry Bagel, MD Director Psoriasis Treatment Center of Central New Jersey East Windsor, NJ
Dr. Bagel discloses the following financial relationships: Speakers’ Bureau, Consultant, Clinical Trials: Amgen, AbbVie, Eli Lilly, Janssen Pharmaceuticals, and Novartis
Alexis Ogdie-Beatty, MD Assistant Professor of Medicine Hospital of the University of Pennsylvania Director, Penn Psoriatic Arthritis Clinic University of Pennsylvania Philadelphia, PA
Dr. Ogdie-Beatty discloses the following financial relationships: Consultant: Novartis Grant/Research Support: Pfizer
Linda Grinnell-Merrick, MS, RN, ANP-BC President, Chapter Development & Governance Chair Rheumatology Nurses Society Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center Rochester, NY
Mrs. Grinnell-Merrick has nothing to disclose regarding financial relationships.
Sara Madonna (Moderator) has nothing to disclose regarding financial relationships.
Publishing Staff Disclosures
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE for Nurses
The Academy for Continued Healthcare Learning has been accredited as an Authorized Provider by the International Association for Continuing Education and training (IACET).
ACHL is authorized by IACET to offer 0.10 CEU for this program. IACET CEUs are accepted by the American Nursing Association. Contact your licensing agency for details. 0.10 CEU = 60 minutes
Disclosure of Unlabeled Use
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Anti-IL-17, anti-IL-23, and JAK inhibitors under investigation for PsA. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact: Katlyn Cooper Program Manager, ACHL email@example.com